Nicox and Kowa Collaborate to Develop and Commercialize NCX 470 in Japan
Shots:
- Nicox and Kowa have signed an agreement to develop & commercialize the former’s NCX 470 (nitric oxide donating bimatoprost eye drop) to reduce intraocular pressure in glaucoma or ocular hypertension patients
- As per the exclusive licensing agreement, Nicox will receive ~$3.23M as an upfront payment, ~$10.78M upon achieving development and regulatory milestones, ~$18.86M milestone payment for sales along with 7%-12% tiered sales-based royalties
- Kowa will cover all development, regulatory, and commercialization costs for NCX 470 in Japan. The company will conduct additional clinical studies in Japanese patients, necessary for regulatory approval along with utilizing the development data from Nicox
Ref: Nicox | Image: Nicox
Related News:- Innoblative’s SIRA RFA Electrosurgical Device Receives a Breakthrough Device Designation from the US FDA for Breast Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
